Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company developing immunotherapies, has announced promising results from its Phase 1b study of azer-cel, an off-the-shelf, allogeneic CAR T ...

Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...

It’s demoralizing to know the final word in a cancer treatment plan can come from a profit-driven decision made in an insurer’s office instead of a doctor.

Marie Hindee experienced a breakthrough in her 15-year battle with chronic lymphocytic leukemia and small lymphocytic lymphoma after undergoing a cutting-edge therapy at Corewell Health Beaumont ...

The potential of STAR-LLD to improve lenalidomide’s therapeutic index suggests an opportunity for use in combination with CAR-T cell therapies.As ...

In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

Having successfully navigated the Humira patent cliff, AbbVie is poised for continued growth.

After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.

Cam Newton says women 'lose value' with more children “Stayed up until 2am in a bidding war trying to win Hulk Hogan’s worn & ...

The FDA granted full approval encorafenib (Braftovi) in combination with cetuximab (Erbitux) and fluorouracil-based ...

BeOne Medicines Q4 earnings and revenue beat the Street's expectations; the outlook missed by a small margin. Read why I have a strong buy rating for ONC stock.

North Platte City Council members and Mayor Brandon Kelliher have scheduled a 4 p.m. tour of the Public Safety Building.